Research-based content. This article is based on published research and publicly available pricing data. It is not medical advice. Do not start, stop, or change any medication without consulting a licensed healthcare professional. See sources below.
Trastuzumab (Herceptin) in India — Biosimilar Price, Manufacturers & Cancer Treatment Access
Approximate Price Comparison (per month supply)
India
$200 – $500
US
$4,500 – $6,000
UK
$1,500 – $3,000
Prices are approximate and vary by dosage, brand, and pharmacy. Based on publicly available data.
Indian Manufacturers
Trastuzumab changed the survival odds for HER2-positive breast cancer from one of the worst to one of the best prognoses. But access remains gatekept by price — $54,000–$72,000 per year in the US.
India cracked this problem years ago. Indian biosimilar trastuzumab costs $2,400–$6,000 for the full 12-month course. Same molecule, same clinical outcomes, 95% lower cost.
The Trastuzumab Revolution — And Its Access Problem
HER2-positive breast cancer accounts for 15-20% of all breast cancers. Before trastuzumab, HER2+ was among the most aggressive subtypes. Trastuzumab transformed it into one of the most treatable, with 5-year survival rates improving dramatically.
But at $4,500–$6,000 per cycle (typically 18 cycles over 12 months), the total treatment cost in the US reaches $54,000–$72,000. Many patients face:
- Insurance prior authorization delays of weeks to months
- High copays even with coverage ($2,000–$5,000 out-of-pocket per year)
- Complete denial if using second-line or maintenance indications
India’s Biosimilar Trastuzumab: A Global Model
India was among the first countries to approve a trastuzumab biosimilar. Today, Indian-made trastuzumab is used across 100+ countries:
| Indian Manufacturer | Brand Name | Regulatory Approvals | Patients Treated |
|---|---|---|---|
| Biocon | CANMAb / Ogivri | US FDA, EMA, WHO PQ | 500,000+ globally |
| Hetero Drugs | Hertraz | CDSCO, WHO PQ | India, Africa, Asia |
| Zydus | Viveldra | CDSCO, EMA filing | India, Europe pipeline |
| Reliance Life Sciences | ReliHer | CDSCO | India |
Biocon’s trastuzumab biosimilar story is particularly significant: it was the first biosimilar trastuzumab to achieve WHO Prequalification, enabling procurement by UNICEF and global health programs at prices that made HER2+ treatment accessible in low-income countries.
Cost Breakdown: Full HER2+ Treatment Course
| Treatment Phase | US Cost | India Cost |
|---|---|---|
| HER2 diagnostic testing | $1,000 – $3,000 | $100 – $300 |
| Chemotherapy (4 cycles AC) | $10,000 – $20,000 | $800 – $2,000 |
| Trastuzumab (18 cycles) | $54,000 – $72,000 | $2,400 – $6,000 |
| Radiation therapy | $15,000 – $30,000 | $1,500 – $3,000 |
| Surgery (lumpectomy/mastectomy) | $15,000 – $40,000 | $2,000 – $5,000 |
| Complete treatment | $95,000 – $165,000 | $6,800 – $16,300 |
The India option saves $88,000–$149,000 on a complete HER2+ breast cancer treatment course.
ENHERTU: The Next-Generation HER2 Drug
ENHERTU (trastuzumab deruxtecan) has an FDA PDUFA date of May 18, 2026 for neoadjuvant HER2+ breast cancer. This antibody-drug conjugate delivers chemotherapy directly to HER2-expressing cancer cells, improving efficacy while reducing systemic side effects.
ENHERTU is priced at approximately $13,000–$15,000 per month in the US. Indian access through licensing agreements is expected, with pricing projected at $1,000–$2,500 per month — following the same pattern as original trastuzumab.
Why Medical Tourists Choose India for Cancer Treatment
Beyond drug pricing, India offers structural advantages for cancer care:
- Specialist density: Major cancer centers have 50-100+ oncologists across subspecialties
- Technology: PET-CT, CyberKnife, proton therapy, genomic profiling all available
- Treatment protocols: Follow NCCN/ESMO guidelines — same evidence-based approach as Western centers
- Volume: Tata Memorial alone treats 70,000+ cancer patients per year — high volume correlates with better outcomes
- Speed: Treatment can begin within days of consultation, compared to weeks of insurance pre-authorization in the US
Practical Guide for Medical Tourists
Starting trastuzumab in India:
- Bring your pathology slides and reports — Indian hospitals can re-confirm HER2 status
- Budget $200–$500 per trastuzumab cycle — paid per cycle at the hospital pharmacy
- Plan for 18 cycles over 12 months — some patients stay in India, others alternate between India and home
- Cardiac monitoring is essential — trastuzumab can affect heart function; Indian hospitals include routine echocardiograms in the treatment protocol
- Cold chain handled by the hospital — trastuzumab requires refrigerated storage; hospital pharmacies manage this
Continuing treatment at home:
If starting trastuzumab in India and continuing elsewhere, request:
- Detailed treatment summary in English
- Specific trastuzumab lot numbers and doses administered
- Cardiac monitoring results (LVEF/echo reports)
- Next scheduled dose date and recommended protocol continuation
Sources & References
- FDA — ENHERTU neoadjuvant HER2+ breast cancer PDUFA date May 18, 2026
- Biocon — Ogivri/CANMAb (trastuzumab biosimilar) prescribing information
- WHO Prequalification — Trastuzumab biosimilar listings, 2026
- The Lancet Oncology — Biosimilar trastuzumab efficacy meta-analysis
- Tata Memorial Hospital — HER2+ breast cancer treatment costs, 2026
- Indian Council of Medical Research — National Cancer Registry Programme, 2025
Frequently Asked Questions
How much does Trastuzumab (Herceptin) cost in India?
Branded Herceptin costs $4,500–$6,000 per cycle in the US. Indian biosimilar trastuzumab (manufactured by Biocon, Hetero, Zydus) costs $200–$500 per cycle — a 90-95% savings. A full 12-month course in India costs $2,400–$6,000 vs $54,000–$72,000 in the US.
Is Indian trastuzumab biosimilar as effective as Herceptin?
Yes. Biocon's trastuzumab biosimilar (Ogivri/CANMAb) has been approved by the US FDA, European EMA, and WHO. Multiple clinical studies and meta-analyses confirm equivalent efficacy and safety. Over 500,000 patients worldwide have been treated with Indian-manufactured trastuzumab biosimilars.
What is ENHERTU and will it be available in India?
ENHERTU (trastuzumab deruxtecan) is an antibody-drug conjugate with a PDUFA date of May 18, 2026 for neoadjuvant HER2+ breast cancer. It represents the next generation of HER2-targeted therapy. Indian access is expected through licensing agreements, with pricing 80-90% below US costs once available.
Which Indian hospital is best for HER2-positive breast cancer?
Tata Memorial Hospital (Mumbai) treats the highest volume of breast cancer patients in India. Other top options include Rajiv Gandhi Cancer Institute (Delhi), HCG Cancer Centre (Bengaluru), and Apollo Cancer Centre (Chennai). All offer trastuzumab biosimilar therapy as standard of care for HER2+ breast cancer at Indian pricing.
Can international patients access trastuzumab during a medical trip to India?
Yes. International patients can start or continue trastuzumab therapy in India. Most oncology hospitals offer treatment packages for medical tourists that include consultation, genomic testing, chemotherapy, and targeted therapy at Indian market prices. Some patients travel to India specifically for the 12-month trastuzumab course, saving $50,000+ over US pricing.
Disclaimer: This content is for informational and educational purposes only, based on published research and publicly available data. It does not constitute medical advice, diagnosis, or treatment recommendations. Drug prices are approximate and vary by dosage, formulation, brand, and pharmacy. Always consult a qualified healthcare professional before making any decisions about medication. Fittour India is not a pharmacy, drug seller, or licensed medical provider.